Free Trial
→ 'This Could Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined' (From Stansberry Research) (Ad) Free BNTX Stock Alerts

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech logo
$120.76 +7.63 (+6.74%)
(As of 11/25/2024 ET)
Compare

BioNTech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings
Sell
0
Hold
4
Buy
12

Based on 16 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$138.79
14.93% Upside
According to the 16 analysts' twelve-month price targets for BioNTech, the average price target is $138.79. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $122.00. The average price target represents a forecasted upside of 14.93% from the current price of $120.76.
Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

Sign Up

BNTX Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24		1 Month Ago
10/28/23 to 10/27/24		3 Months Ago
8/29/23 to 8/28/24		1 Year Ago
11/27/22 to 11/27/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$138.79$135.54$109.09$153.69
Forecasted Upside14.93% Upside22.68% Upside23.69% Upside58.67% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside14.93% Upside17,640.32% Upside6.38% Upside
News Sentiment Rating
Neutral News

See Recent BNTX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/19/2024Berenberg Bank
2 of 5 stars		H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy$130.00+27.61%
11/19/2024Evercore ISI
2 of 5 stars		C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeIn-Line ➝ Outperform$110.00 ➝ $125.00+22.71%
11/18/2024HC Wainwright
2 of 5 stars		 Reiterated RatingBuy ➝ Buy$150.00 ➝ $150.00+50.42%
11/14/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$171.00 ➝ $171.00+51.60%
11/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy$90.00 ➝ $137.00+26.99%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$132.00 ➝ $122.00+10.28%
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$125.00 ➝ $124.00+10.95%
10/7/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$97.00 ➝ $136.00+10.88%
9/24/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeEqual Weight ➝ Overweight$93.00 ➝ $145.00+28.26%
9/19/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$95.00 ➝ $150.00+33.87%
9/18/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$97.00 ➝ $131.00+5.04%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$96.00 ➝ $150.00+21.49%
9/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$125.00 ➝ $150.00+23.75%
8/2/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Strong-Buy
5/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$123.00 ➝ $122.00+32.90%
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Perform
5/17/2023Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$165.00 ➝ $170.00+60.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:49 AM ET.


Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 25, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE recently reported earnings per share (EPS) of $0.81, significantly exceeding analysts' expectations of a loss of $1.26, indicating strong financial performance and potential for growth.
  • The company's revenue for the quarter was $1.24 billion, far surpassing the forecast of $514.08 million, showcasing robust demand for its products and services.
  • BioNTech SE's stock price is currently at $101.87, reflecting a 2.2% increase, which may indicate positive market sentiment and potential for further appreciation.
  • Multiple analysts have upgraded their ratings on BioNTech SE, with HSBC Global Research raising it to a "strong-buy" and several others setting price targets above the current stock price, suggesting confidence in the company's future performance.
  • The company has a strong balance sheet with a low debt-to-equity ratio of 0.01, indicating financial stability and reduced risk for investors.

BioNTech
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BioNTech SE for these reasons:

  • Despite recent positive earnings, BioNTech SE has a negative return on equity of 2.35%, which may raise concerns about the company's ability to generate profit from its equity investments.
  • The company has a negative net margin of 15.16%, indicating that it is currently spending more to generate revenue than it is earning, which could be a red flag for potential investors.
  • Analysts forecast that BioNTech SE will post an EPS of -3.47 for the current year, suggesting ongoing challenges in achieving profitability.
  • While the stock has seen recent upgrades, there are still four analysts who have rated it as a hold, indicating that not all market participants are convinced of its growth potential.
  • The stock has a beta of 0.26, suggesting lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $138.79, with a high forecast of $171.00 and a low forecast of $122.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 14.93% based on their 12-month stock forecasts.

Over the previous 90 days, BioNTech's stock had 5 upgrades by analysts.

Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.81 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BNTX compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:BNTX) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Crypto 101 Media | Sponsored
140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)
140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...
Investors Alley | Sponsored
What Are Buffett, Dalio, and Druckenmiller So Worried About?
"This Will Be Worse Than The Great Depression, The Dot-Com Crash, And The 2008 Crisis Combined" According t...
Stansberry Research | Sponsored